ESTRO 2022 - Abstract Book

S1198

Abstract book

ESTRO 2022

The mean pre-treatment baseline IPSS was 6.96 points, increasing to 16.23 at 3 months after implantation and progressively decreasing to 7.14 points at 5.5 years of follow-up, which shows a mean decrease of 0.18 points. Similarly, the mean initial quality of life was 1.54 points, reaching 3.18 at 3 months after treatment and decreasing to 1.42 at 5.5 years of follow-up (mean decrease of 0.12 points). The mean initial IIEF-6 was 13.13 points decreasing to 8.26 at 3 months and increasing again to 11.45 at 5.5 years follow- up (mean decrease of 1.68 points). Mean PSA at 5.5 years decreased to 0.16 ng/mL. Conclusion LDR brachytherapy is an effective treatment with very good long-term tolerability as evidenced by patient-reported quality of life throughout follow-up.

PO-1413 Dose-escalated hypofractionated radiotherapy to 66Gy in localized prostate cancer: long-term results

A. Lazo Prados 1 , A. De la Torre-Luque 2 , G. Arregui Castillo 3 , E. Lopez Ramirez 4 , M.I. Nuñez Torres 5

1 H.U. San Cecilio, Radiation Oncology, Granada, Spain; 2 Complutense University, Legal Medicine, Psychiatry and Pathology, Madrid, Spain; 3 GenesisCare, Department of Physics , Granada, Spain; 4 GenesisCare , Chief Medical Office, Madrid, Spain; 5 Granada University, Department of Radiology and Physical Medicine, Granada, Spain Purpose or Objective Hypofractionated radiation therapy (HFRT) is an effective treatment for localized prostate cancer (Pca) that has demonstrated to be equivalent to conventional schedules in terms of biochemical control and toxicity. On the other hand, conventional fractionated dose-escalation has shown to improve biochemical control and distant metastases, but it does not improve overall survival. This study aimed to provide some clinical outcomes regarding effectiveness, toxicity and quality of life in PCa patients treated with dose-escalated HFRT to a dose of 66 Gy delivered via Volume Modulated Arc Therapy (VMAT). Materials and Methods One hundred and twenty-two patients (122) patients with localized PCa were retrospectively evaluated. They received 66 Gy in 22 fractions (3 Gy/fraction, 5 fractions/week) using VMAT, between 2011-2016. Treatment effectiveness was measured by failure-free survival and overall survival rates. Toxicity was assessed according to the criteria of RTOG/EORTC. Quality of life (QoL) was longitudinally evaluated, at a median of 2 and 5 years after RT, according to the EPIC-26 questionnaire score. Results Median follow-up was 75 months . The overall survival and the biochemical failure-free survival rate was 93.8% and 94.2%, respectively. No patients died from PCa (PCa specific survival was 100%) The incidence of acute grade 2 or higher gastrointestinal (GI) and genitourinary (GU) toxicity was 9.84% and 28.69%, respectively. The incidence rate of late grade 2 or higher GI and GU toxicity was 1.64% and 4.10%, respectively. EPIC scores generally showed excellent results with a slight decrease in QoL related to the incontinence domain (Table 1).

Conclusion HFRT to 66 Gy with VMAT is associated with excellent biochemical control and overall survival results, low toxicity and good reported QoL outcomes.